Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Recruiting · NCT06482905 · Registry updated 2026-03-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, malignant glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 | 2026-03-24 | NCT06482905 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Tiantan Hospital | 307 |
| Mayo Clinic | 970 |
| Tcelltech Inc. | 4 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Tiantan Hospital | Beijing | China | 2 |
| Mayo Clinic in Arizona | Phoenix | United States | 14 |
| Mayo Clinic in Florida | Jacksonville | United States | 89 |
| Mayo Clinic in Rochester | Rochester | United States | 687 |